In the BioHarmony Drug Report Database

"Preview" Icon

Loncastuximab tesirine

Zynlonta (loncastuximab tesirine) is an antibody pharmaceutical. Loncastuximab tesirine was first approved as Zynlonta on 2021-04-23. It is used to treat large b-cell lymphoma diffuse in the USA. It is known to target B-lymphocyte antigen CD19.

 

Trade Name

 

Zynlonta
 

Common Name

 

loncastuximab tesirine
 

ChEMBL ID

 

CHEMBL4297778
 

Indication

 

large b-cell lymphoma diffuse
 

Drug Class

 

Monoclonal antibodies: chimeric, tumors as target

Image (chem structure or protein)

Loncastuximab tesirine structure rendering